Rafael Holdings and Cyclo Therapeutics announce their merger to advance the development of Trappsol® Cyclo™ for treating Niemann-Pick Disease Type C1. This rare and fatal genetic disease has no approved treatment options.
Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ has completed enrollment. Interim analysis results are anticipated in mid-2025. Rafael Holdings will provide funding for the trial’s interim analysis.
The merger combines Rafael Holdings’ resources with Cyclo Therapeutics’ expertise in developing treatments for unmet medical needs. Rafael Holdings has invested in Cyclo Therapeutics since March 2023, supporting the company’s progress in enrolling in the TransportNPC™ clinical trial.
Bill Conkling, President and CEO of Rafael Holdings, emphasizes the merger’s strategic alignment. Cyclo Therapeutics’ successful enrollment in the pivotal Phase 3 trial for Trappsol® Cyclo™ strengthens the combined entity’s focus on delivering innovative therapies for Niemann-Pick Disease Type C1.
N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics, acknowledges the partnership’s benefits in reaching this milestone. The merger with Rafael Holdings provides a strong financial foundation and experienced leadership to accelerate the development of Trappsol® Cyclo™ as a potential treatment option for patients battling Niemann-Pick Disease Type C1.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
